Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

About this update from Dare Bioscience, Inc.

First consumer health product positions Daré for revenue generation while expanding its women's health leadership platform Access the segment here SAN DIEGO, June 25, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in a  Virtual Investor "What This Means" segment highlighting the company's recent news announcing the upcoming June 2026 commercial launch of Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort. For the segment, Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, discussed the upcoming launch of Flora Sync LF5™ and its significance as the company's first consumer health product and opportunity to generate direct product revenue. The conversation explored how Flora Sync LF5 fits within Daré's broader strategy of building a diversified women's health company, while advancing a pipeline of innovative clinical-stage programs. Ms. Johnson also highlighted the science behind the product's vagina-specific formulation, its role within the company's mission to address unmet needs in women's health through accessible, evidence-based solutions, and the future growth potential of the DARE to RESTORE™ brand. The Virtual Investor "What This Means" segment featuring Daré Bioscience is now available here . ABOUT DARÉ BIOSCIENCE, INC. Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs. For decades, women have been told to "wait it out" or "live with it," while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré is working to change that. Learn more at  darebioscience.com . FORWARD-LOOKING STATEMENTS Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "prepare," "seek," "should," "would," "target," "objective," "positioned," or the negative version of these words and similar expressions.

View stock analysis, news, and events for Dare Bioscience, Inc.